dBET6

Catalog No.S8762 Batch:S876203

Print

Technical Data

Formula

C42H45ClN8O7S

Molecular Weight 841.37 CAS No. 1950634-92-0
Solubility (25°C)* In vitro DMSO 100 mg/mL (118.85 mM)
Ethanol 33 mg/mL (39.22 mM)
Water Insoluble
In vivo (Add solvents to the product individually and in order)
Clear solution
5%DMSO 40%PEG300 5%Tween80 50%ddH2O
5.0mg/ml Taking the 1 mL working solution as an example, add 50 μL of 100 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to make it clear; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results. 
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description dBET6 is a highly cell-permeable PROTAC degrader of BET bromodomains with an IC50 of 14 nM for BRD4 binding. dBET6 also induces c-MYC downregulation and apoptosis.
Targets
BRD4 [1]
14 nM
In vitro

dBET6 is a highly cell-permeable degrader of BET bromodomains. It is potent in most cancer cell lines. dBET6 features highly increased cellular potency with evident degradation in the sub-nanomolar range. Treatment with 100 nM dBET6 leads to degradation of BRD4 after 1 hr, prompting subsequent downregulation of c-MYC and induction of apoptosis. dBET6 disrupts global productive transcription elongation. dBET6 treatment leads to a widespread decrease in steady-state mRNA levels, but observed an incommensurate impact on expression of members of the core regulatory circuitry of leukemogenic transcription factors. The collapse of the core transcriptional machinery prompted by BET degradation precedes a robust apoptotic response, of apparent translational significance[1].

In vivo

dBET6 is well tolerated. Upon dBET6 treatment, a significant reduction of leukemic burden is observed in a disseminated mouse model of T-ALL. Moreover, mice treated with dBET6 (7.5 mg/kg BID) exhibits a significant survival benefit compared to mice treated with vehicle control or JQ1 (20 mg/kg QD)[1].

Protocol (from reference)

Cell Assay:

[1]

  • Cell lines

    MOLT4 cells deficient in CRBN expression

  • Concentrations

    0.05, 0.1, 0.5, 1 μM

  • Incubation Time

    3 hr

  • Method

    MOLT4 cells deficient in CRBN expression are treated with various concentrations of either dBET1 or dBET6 for 3 hr. Cells are collected by centrifugation, washed once with PBS and transferred into PCR tubes, spun down and incubated at 47.5°C for 3 min. After a subsequent incubation for 3 min on 25°C, cells are lysed by addition of 30 µL lysis buffer and three repeated freeze-thaw cycles using liquid nitrogen.

Animal Study:

[1]

  • Animal Models

    Male CD-1 mice

  • Dosages

    10 mg/kg

  • Administration

    i.p.

Selleck's dBET6 has been cited by 11 publications

Cell-type-specific tumour sensitivity identified with a bromodomain targeting PROTAC in adenoid cystic carcinoma [ J Pathol, 2024, 262(1):37-49] PubMed: 37792636
Increased expression of BRD4 isoforms long (BRD4-L) and short (BRD4-S) promotes chemotherapy resistance in high-grade serous ovarian carcinoma [ Genes Cancer, 2023, 10.18632/genesandcancer.233] PubMed: 37705995
Increased expression of BRD4 isoforms long (BRD4-L) and short (BRD4-S) promotes chemotherapy resistance in high-grade serous ovarian carcinoma [ Genes Cancer, 2023, 14:56-76] PubMed: 37705995
BRD2 inhibition blocks SARS-CoV-2 infection by reducing transcription of the host cell receptor ACE2 [ Nat Cell Biol, 2022, 24(1):24-34] PubMed: 35027731
Structure-guided discovery of novel potent and efficacious proteolysis targeting chimera (PROTAC) degrader of BRD4 [ Bioorg Chem, 2021, 115:105238] PubMed: 34390970
Epigenomic landscape and 3D genome structure in pediatric high-grade glioma [ Sci Adv, 2021, 7(23)eabg4126] PubMed: 34078608
BRD2 inhibition blocks SARS-CoV-2 infection in vitro by reducing transcription of the host cell receptor ACE2 [ bioRxiv, 2021, 2021.01.19.427194] PubMed: 33501440
Viral E Protein Neutralizes BET Protein-Mediated Post-Entry Antagonism of SARS-CoV-2 [ bioRxiv, 2021, 2021.11.14.468537] PubMed: 34816261
Kinetic Detection of E3:PROTAC:Target Ternary Complexes Using NanoBRET Technology in Live Cells [ Methods Mol Biol, 2021, 2365:151-171] PubMed: 34432243
ASXL3 bridges BRD4 to BAP1 complex and governs enhancer activity in small cell lung cancer [ Genome Med, 2020, 12(1):63] PubMed: 32669118

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.